Vitreous floaters (Myodesopsia)

Myodesopsia, also known as floaters, are a visual phenomena caused by opacities in the vitreous that cast shadows on the retina, generating the sensation in the observer of seeing floaters, dark spots or nodules, among other elements, which interfere with their field of vision.³

They are the most common symptom associated with posterior vitreous detachment (PVD) caused by increased oxidative stress and ageing.³

Introducing VISUfly® Sachets

VISUfly® is a gluten free and lactose free dietary supplement designed to help protect cells against oxidative stress. It contains a unique blend of active ingredients including fruit enzymes and collagen. The key ingredients in VISUfly® helps supports those suffering from vitreous floaters (myodesopsia).^1,2*

The role of the ingredients within VISUfly®:²

•  Bromelain – A natural enzyme from pineapple with hydrolytic and proteolytic properties that aid in protein breakdown.
•  Ficain – Extracted from fig latex, supports the solubilisation of proteins like collagen and elastin.
•  Papain – Derived from papaya, promotes protein digestion into beneficial peptides and amino acids.
•  Glutathione – A potent antioxidant naturally present in the body, essential for cell defence.
•  Peptan® Collagen – Patented hydrolysed bovine collagen, vital for connective tissue health, naturally decreasing from age 25.
•  Vitamin C – Supports collagen formation and protects cells from oxidative damage.

VISUfly® may be suitable for adults experiencing vitreous floaters, including the elderly population, post-cataract surgery patients, individuals with PVD, axial myopia or diabetes, and those seeking nutritional support for connective tissue health and cellular protection from oxidative stress.^3-8

 Environmentally Conscious

In line with VISUfarma UK’s commitment to sustainability, we pledge to offset all usage of VISUfly® in our mission as a Carbon Net Zero and Plastic Neutral company.

 Benefits of VISUfly®:

• Lactose free.²
• Gluten free.²
• Pleasant orange flavouring.²
• Additional portion of nutrients to your daily diet.^2**
• Presented in an easy-to-take daily sachet.²
• A unique blend of natural enzymes, antioxidants, and collagen – whose key ingredients help provide support for those with vitreous floaters (myodesopsia).^1,2*
• Supports cellular protection from oxidative stress.²
• Promotes collagen health for skin, joints, and connective tissues.²

VISUfly® offers a convenient daily nutritional option for those seeking support for visual disturbances commonly associated with ageing and oxidative stress^1,2*

VISUfly® is available in a box of 30 x 3g sachets and is available from all major optical wholesalers now. For more information, please call VISUfarma on 0113 4680661 or e-mail UKcustomerservices@visufarma.com

About VISUfarma

VISUfarma is a pan-European customer-focused, highly innovative ophthalmic pharmaceutical

company with a clear mission: To deliver top-quality products and cutting-edge therapeutic

solutions that improve the lives of patients and meet the evolving needs of eye care professionals. We are an ambitious, customer-centred and fast growing ophthalmology company, commercialising a broad portfolio of pharmaceutical products and medical devices across Europe.

*A study showed that those taking 2 capsules per day containing 190 mg bromelain, 95 mg papain and 95 mg ficin, had a 70% disappearance rate in symptomatic vitreous opacities (SVO) after 3 months, with no serious side effects or discomfort during treatment. This increased to a 75% disappearance rate with 3 capsules per day, showcasing a dose-dependent floater reduction.¹

 **The supplements are not intended as substitutes for a varied and balanced diet and a healthy lifestyle.

 References

1.         Takeuchi M, et al. Treatment of Symptomatic Vitreous Opacities with Pharmacologic Vitreolysis Using a Mixture of Bromelain, Papain and Ficin Supplement. Appl. Sci. 2020, 10, 5901.

2.          VISUfly® Instructions for Use (IFU).

3.         Milston R, et al. Vitreous floaters: Etiology, diagnostics, and management. Survey of ophthalmology. 2016;61;211-227.

4.         Brown GC, et al. Photopsias: A key to diagnosis. Ophthalmology 2015;122:2084-2094.

5.         Webb BF, et al. Prevalence of vitreous floaters in a community sample of smartphone users. Int J Ophthalmol. 2013;6(3):402-405.

6.         Gale, J. Ikuno, Y. Myopic vitreopathy, in Sebag J (ed) Vitreous – in Health and Disease. New York, Springer-Verlag. 2014;113-129.

7.         Mirshahi A, et al. Incidence of posterior vitreous detachment after cataract surgery. J Cataract Refract Surg. 2009;35:971-991.

8.         National Eye Institute. https://www.nei.nih.gov/espanol/aprenda-sobre-la-salud-ocular last accessed January 2026.

VISU/UK/VFLY/0005 | Date of Preparation: January 2026